Tramadol

BioTech Hot List BVL, HYTM, VRX, PIP, PLMO

23.06.10

Biovail Corporation (Biovail) is a specialty pharmaceutical company. The Company focuses on developing and commercializing products in specialty central nervous system (CNS) disorders. As of December 31, 2009, the Company’s products within its development pipeline included Staccato loxapine, Pimavanserin, BVF-018, Fipamezole and GDNF. In May 2009, the Company acquired the United States commercialization rights to Wellbutrin XL from The GlaxoSmithKline Group of Companies (GSK). In June 2009, it acquired the worldwide development and commercialization rights to the entire portfolio of tetrabenazine products, including Xenazine and Nitoman, held by Cambridge Laboratories (Ireland) Ltd. (Cambridge).

Wellbutrin XL (bupropion hydrochloride extended release tablets) is an extended-release formulation of bupropion indicated for the treatment of depression in adults. Xenazine (tetrabenazine) is indicated for the treatment of chorea associated with Huntington’s disease. Huntington’s disease is a rare, inherited neurological disorder that is passed from parent to child through a gene mutation. Tetrabenazine has been approved for use in a number of countries in Europe and worldwide. In April 2009, Aplenzin (bupropion hydrobromide) was launched in the United States by sanofi-aventis U.S. LLC (sanofi-aventis U.S.). Aplenzin is an extended-release formulation of bupropion hydrobromide for the treatment of major depressive disorder. Aplenzin was approved by the United States Food & Drug Administration (FDA).

Source: Live Trading News